These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 10911025)

  • 61. In vitro and in vivo detection of functional somatostatin receptors in canine insulinomas.
    Robben JH; Visser-Wisselaar HA; Rutteman GR; van Rijk PP; van Dongen AJ; Voorhout G; van den Ingh TS; Hofland LJ; Lamberts SW
    J Nucl Med; 1997 Jul; 38(7):1036-42. PubMed ID: 9225787
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Somatostatin-receptor-based imaging and therapy of gastroenteropancreatic neuroendocrine tumors.
    Kwekkeboom DJ; Kam BL; van Essen M; Teunissen JJ; van Eijck CH; Valkema R; de Jong M; de Herder WW; Krenning EP
    Endocr Relat Cancer; 2010 Mar; 17(1):R53-73. PubMed ID: 19995807
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Radiolabeled gastrin/CCK analogs in tumor diagnosis: towards higher stability and improved tumor targeting.
    Kaloudi A; Nock BA; Krenning EP; Maina T; De Jong M
    Q J Nucl Med Mol Imaging; 2015 Sep; 59(3):287-302. PubMed ID: 26158215
    [TBL] [Abstract][Full Text] [Related]  

  • 64. 64Cu-labeled alpha-melanocyte-stimulating hormone analog for microPET imaging of melanocortin 1 receptor expression.
    Cheng Z; Xiong Z; Subbarayan M; Chen X; Gambhir SS
    Bioconjug Chem; 2007; 18(3):765-72. PubMed ID: 17348700
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Value of 111In-DOTA-lanreotide and 111In-DOTA-DPhe1-Tyr3-octreotide in differentiated thyroid cancer: results of in vitro binding studies and in vivo comparison with 18F-FDG PET.
    Rodrigues M; Traub-Weidinger T; Leimer M; Li S; Andreae F; Angelberger P; Dudczak R; Virgolini I
    Eur J Nucl Med Mol Imaging; 2005 Oct; 32(10):1144-51. PubMed ID: 15909194
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Molecular imaging of cancer with radiolabeled peptides and PET.
    Vāvere AL; Rossin R
    Anticancer Agents Med Chem; 2012 Jun; 12(5):462-75. PubMed ID: 22292762
    [TBL] [Abstract][Full Text] [Related]  

  • 67. In situ radiotherapy with 111In-pentetreotide. State of the art and perspectives.
    McCarthy KE; Woltering EA; Anthony LB
    Q J Nucl Med; 2000 Mar; 44(1):88-95. PubMed ID: 10932605
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Treatment of advanced neuroendocrine tumours with radiolabelled somatostatin analogues.
    Kaltsas GA; Papadogias D; Makras P; Grossman AB
    Endocr Relat Cancer; 2005 Dec; 12(4):683-99. PubMed ID: 16322317
    [TBL] [Abstract][Full Text] [Related]  

  • 69. A gallium-labeled DOTA-alpha-melanocyte- stimulating hormone analog for PET imaging of melanoma metastases.
    Froidevaux S; Calame-Christe M; Schuhmacher J; Tanner H; Saffrich R; Henze M; Eberle AN
    J Nucl Med; 2004 Jan; 45(1):116-23. PubMed ID: 14734683
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Development and application of peptide-based radiopharmaceuticals.
    Dijkgraaf I; Boerman OC; Oyen WJ; Corstens FH; Gotthardt M
    Anticancer Agents Med Chem; 2007 Sep; 7(5):543-51. PubMed ID: 17896914
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Radiopharmaceutical development of radiolabelled peptides.
    Fani M; Maecke HR
    Eur J Nucl Med Mol Imaging; 2012 Feb; 39 Suppl 1():S11-30. PubMed ID: 22388624
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Receptor-mediated tumor targeting with radiopeptides. Part 1. General concepts and methods: applications to somatostatin receptor-expressing tumors.
    Eberle AN; Mild G; Froidevaux S
    J Recept Signal Transduct Res; 2004; 24(4):319-455. PubMed ID: 15648449
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Radiolabeled peptides and proteins in cancer therapy.
    Wängler C; Buchmann I; Eisenhut M; Haberkorn U; Mier W
    Protein Pept Lett; 2007; 14(3):273-9. PubMed ID: 17346233
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Diagnosis and therapy are walking together on radiopeptides' avenue.
    Mansi L; Virgolini I
    Eur J Nucl Med Mol Imaging; 2011 Apr; 38(4):605-12. PubMed ID: 21365250
    [No Abstract]   [Full Text] [Related]  

  • 75. Application of radiolabeled peptides in tumor imaging and therapy.
    Mohtavinejad N; Shafiee Ardestani M; Khalaj A; Pormohammad A; Najafi R; Bitarafan-Rajabi A; Hajiramezanali M; Amanlou M
    Life Sci; 2020 Oct; 258():118206. PubMed ID: 32758623
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Mini-PEG spacering of VAP-1-targeting 68Ga-DOTAVAP-P1 peptide improves PET imaging of inflammation.
    Autio A; Henttinen T; Sipilä HJ; Jalkanen S; Roivainen A
    EJNMMI Res; 2011 Jul; 1(1):10. PubMed ID: 22214508
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Radiolabeled peptides in nuclear oncology: influence of peptide structure and labeling strategy on pharmacology.
    Maecke HR
    Ernst Schering Res Found Workshop; 2005; (49):43-72. PubMed ID: 15524210
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Radiolabeled peptides: valuable tools for the detection and treatment of cancer.
    Fani M; Maecke HR; Okarvi SM
    Theranostics; 2012; 2(5):481-501. PubMed ID: 22737187
    [TBL] [Abstract][Full Text] [Related]  

  • 79. 68Ga-DOTA-D Phe1-Tyr3-Octreotide (DOTATOC)-PET/CT in a Suspected Case of Recurrent Meningioma.
    Jain S; Gupta A; Jain A
    Indian J Nucl Med; 2017; 32(2):164. PubMed ID: 28533656
    [No Abstract]   [Full Text] [Related]  

  • 80. Different Modes of Acid-Promoted Cyclooligomerization of 4-(4-Thiosemicarbazido)butan-2-one Hydrazone: 14-Membered versus 28-Membered Polyazamacrocycle Formation.
    Fesenko AA; Grigoriev MS; Arion VB; Shutalev AD
    J Org Chem; 2022 Dec; 87(23):15722-15731. PubMed ID: 36383744
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.